Elicio Therapeutics Reports Inducement Grants
Stocks in this Quantisnow insightHealth Care
Historical context for ELTX
Across the 7 sessions after earlier ELTX headlines, the stock closed higher 1 times and lower 5 times, with a median move of 2.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ELTX | SPY |
|---|---|---|---|
| Dec 16, 2025 | Elicio Therapeutics Reports Inducement Grants | -4.3% | -0.3% |
| Dec 11, 2025 | Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial | +4.0% | +0.2% |
| Nov 19, 2025 | Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer | -5.5% | +0.4% |
| Nov 14, 2025 | Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates | -2.2% | -0.0% |
| Nov 7, 2025 | Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC | -2.2% | +0.1% |
| Nov 3, 2025 | Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting | -0.4% | +0.2% |
Quantisnow market dataNASDAQ
ELTX
Elicio Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Get push alerts for ELTX
Full ELTX profile on Quantisnow Follow ELTX and get a push notification the moment its next story breaks.